SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Halozyme Therapeutics Q1 EPS $(0.040) Misses $(0.020) Estimate, Sales $25.354M Miss $42.960M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly losses of $(0.040) per share which missed the analyst consensus estimate of $(0.020) by 100 percent. This is a 500 percent decrease over earnings of $0.010 per share

Benzinga · 05/11/2020 20:01

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly losses of $(0.040) per share which missed the analyst consensus estimate of $(0.020) by 100 percent. This is a 500 percent decrease over earnings of $0.010 per share from the same period last year. The company reported quarterly sales of $25.354 million which missed the analyst consensus estimate of $42.960 million by 40.98 percent. This is a 55.48 percent decrease over sales of $56.949 million the same period last year.